METHYLIN ER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for METHYLIN ER (METHYLIN ER).
Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.
| Metabolism | Primarily de-esterified by carboxylesterase 1 (CES1) to the inactive metabolite ritalinic acid. Minor hepatic metabolism via CYP2D6. |
| Excretion | Renal (90% as metabolites, <1% unchanged). Biliary/fecal: <2%. |
| Half-life | Mean 3-6 hours in adults; longer in children (4-8 hours). Clinical context: steady-state reached within 2 days; dosing every 8-12 hours. |
| Protein binding | Methylphenidate: 10-33%, primarily to albumin. Metabolite ritalinic acid: ~50% bound. |
| Volume of Distribution | 2.6-4.0 L/kg. Indicates extensive tissue distribution. |
| Bioavailability | Oral: 11-52% (low and variable due to first-pass metabolism). |
| Onset of Action | Oral ER: 0.5-1 hour (immediate release component); peak effect 2-4 hours. |
| Duration of Action | Oral ER: 8-12 hours. Note: duration may be shorter in children; individual variation requires titration. |
| Molecular Weight | 269.77 |
20-60 mg orally once daily in the morning
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No adjustment needed for GFR >30 mL/min; insufficient data for GFR <30 mL/min |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B or C: reduce dose by 50% |
| Pediatric use | 6 years and older: 18-54 mg orally once daily; weight-based: 0.3-1 mg/kg/dose, max 54 mg/day; not recommended under 6 years |
| Geriatric use | Start at low end of dosing range (20 mg daily) due to potential increased sensitivity; monitor cardiovascular status |
| 1st trimester | Insufficient human data; animal studies show possible increased risk of malformations. Use only if potential benefit justifies risk. |
| 2nd trimester | Limited data; may cause fetal tachycardia or growth restriction. Consider alternative treatments. |
| 3rd trimester | Use in third trimester may lead to neonatal withdrawal syndrome, including irritability, feeding difficulties, and respiratory distress. Avoid use near term. |
Clinical note
Comprehensive clinical and safety monograph for METHYLIN ER (METHYLIN ER).
| Placental transfer | Methylphenidate crosses the placenta; concentrations in cord blood are approximately 40-50% of maternal plasma levels. |
| Breastfeeding | Methylphenidate is excreted into breast milk in low concentrations (relative infant dose approximately 0.2-0.7%). Monitor infant for agitation, poor feeding, and insomnia. Manufacturers recommend caution; consider benefits of breastfeeding versus potential risk of exposure. |
■ FDA Black Box Warning
Abuse and dependence: CNS stimulants, including methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
| Serious Effects |
Marked anxiety, tension, or agitationGlaucomaMotor tics or family history of Tourette's syndromeConcurrent treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOIHypersensitivity to methylphenidate or any componentSevere hypertension or cardiovascular diseaseThyrotoxicosis
| Precautions | Risk of abuse and dependence, Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with pre-existing structural cardiac abnormalities or other serious heart problems, Blood pressure and heart rate increase, Psychiatric adverse events: exacerbation of pre-existing psychosis, mania, aggression, new psychotic or manic symptoms, Seizures: may lower seizure threshold, Priapism, Peripheral vasculopathy including Raynaud's phenomenon, Long-term suppression of growth in pediatric patients |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) – limited data suggest low risk. |
| Teratogenic Risk | Methylphenidate is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of fetal anomalies (cardiac, skeletal) at high doses. Second trimester: Potential for decreased fetal growth with chronic use. Third trimester: Risk of neonatal withdrawal syndrome (tachycardia, irritability, poor feeding) and premature delivery. |
| Fetal Monitoring | Maternal: Blood pressure, heart rate, weight, and mental status. Fetal: Ultrasound for growth parameters every 4-6 weeks in chronic use; consider fetal echocardiogram if high-dose exposure in first trimester. Neonatal: Observe for withdrawal symptoms for 48 hours after delivery. |
| Fertility Effects | No direct evidence of impaired fertility in humans. In animal studies, high doses caused decreased implantation and sperm count. Reversible upon discontinuation. |
| Avoid alcohol, which may increase risk of cardiovascular side effects. Food does not significantly affect absorption of extended-release formulation, but acidic foods/beverages may reduce absorption if taken simultaneously. |
| Clinical Pearls | Do not crush or chew extended-release tablets; capsule can be opened and sprinkled on applesauce. Monitor for weight loss and growth suppression in pediatric patients. Avoid use within 14 days of MAOIs. Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or history of substance abuse. May lower seizure threshold. |
| Patient Advice | Take exactly as prescribed; do not alter dose or frequency without consulting doctor. · Swallow tablets whole; do not crush, chew, or break. · Avoid alcohol while taking this medication. · Report any chest pain, shortness of breath, or fainting. · Regular monitoring of blood pressure and heart rate is needed. · May cause difficulty sleeping; take last dose of short-acting forms early in the day. · Store at room temperature away from moisture and heat. |